Investigation of the mechanism of Bark of Ailanthus altissima in the treatment of ulcerative colitis based on network pharmacology and experimental verification.
Ailanthus altissima
Network Pharmacology
PI3K/AKT
UHPLC-MS/MS
Ulcerative Colitis
Journal
Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310
Informations de publication
Date de publication:
09 Oct 2024
09 Oct 2024
Historique:
received:
07
07
2024
revised:
04
10
2024
accepted:
05
10
2024
medline:
12
10
2024
pubmed:
12
10
2024
entrez:
11
10
2024
Statut:
aheadofprint
Résumé
The bark of Ailanthus altissima (Mill.) Swingle (BAA), a widely used Chinese medicinal herb in traditional remedies for bowel disorders, has yet to be explored in the context of ulcerative colitis (UC), and its therapeutic mechanisms remain unclear. This study integrated network pharmacology and experimental validation to investigate the effects and underlying mechanisms of BAA in treating UC. First, UPLC-MS/MS analysis was employed to identify the chemical constituents of BAA. Network pharmacology was then applied to analyze the potential mechanisms of BAA based on these identified compounds. Lastly, a dextran sulfate sodium (DSS)-induced UC mouse model was utilized to assess BAA's therapeutic efficacy, with Western blotting performed to examine changes in protein expression within the key pathway influenced by BAA. UPLC-MS/MS and SwissADME analysis identified 223 active compounds in BAA. Network pharmacology suggested that the PI3K/AKT pathway may serve as a primary mechanism by which BAA exerts its anti-UC effects. In the DSS-induced UC mouse model, BAA significantly mitigated colonic injury, reduced DAI scores, and promoted weight recovery in mice. Additionally, BAA downregulated pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6, thereby suppressing inflammatory responses in the colon. Western blot analysis further demonstrated that BAA primarily inhibited the PI3K/AKT pathway in UC mouse colon tissue. This study highlights that BAA effectively reduces colonic inflammation and preserves intestinal mucosal integrity, likely through the inhibition of PI3K/AKT pathway activity, positioning it as a potential treatment for UC.
Identifiants
pubmed: 39393560
pii: S0378-8741(24)01215-7
doi: 10.1016/j.jep.2024.118916
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
118916Informations de copyright
Copyright © 2024. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: